National Institutes of Health (NIH)

NIH PAR-21-339: 2024 Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Programs (R25 - Clinical Trial Not Allowed)

No applicants  // Limit: 1 // Tickets Available: 1 

 

To accomplish the stated overarching goal, this FOA will provide support to recipients of Clinical and Translational Science Awards (CTSA) for creative educational activities with a primary focus on research experiences designed to ensure that the participants receive exposure to the scientific and operational principles underlying each step of the translational process so that they can apply these principles to clinical and translational science research areas such as: 1) pre-clinical research, 2) clinical research, 3) clinical implementation, and 4) public health.

  • Research Experiences

 

NCATS solicits the submission of one set of companion applications. With this solicitation for the R25 application, a separate, companion FOA solicits applications for a required UM1 (PAR-21-293: Clinical and Translational Science Award). The UM1 and initial R25 applications must be submitted concurrently; an R25 application without the required companion UM1 application will not be reviewed. The R25 application will only be awarded if the UM1 application is awarded. Resubmission of an R25 without the required UM1 will be allowed only if the UM1 application is awarded.

The sponsoring institution must assure support for the proposed program. Appropriate institutional commitment to the program includes the provision of adequate staff, facilities, and educational resources that can contribute to the planned program

The PD/PI should be an established investigator in the scientific area in which the application is targeted and capable of providing both administrative and scientific leadership to the development and implementation of the proposed program. The PD/PI will be expected to monitor and assess the program and submit all documents and reports as required.

The UM1 PD(s)/PI(s) may not be a PD(s)/PI(s) on the R25 award.

NCATS solicits the submission of one set of companion applications. With this solicitation for the R25 application, a separate, companion FOA solicits applications for a required UM1 (PAR-21-293: Clinical and Translational Science Award). The UM1 and initial R25 applications must be submitted concurrently; an R25 application without the required companion UM1 application will not be reviewed. The R25 application will only be awarded if the UM1 application is awarded. Resubmission of an R25 without the required UM1 will be allowed only if the UM1 application is awarded. The sponsoring institution must assure support for the proposed program. Appropriate institutional commitment to the program includes the provision of adequate staff, facilities, and educational resources that can contribute to the planned program

• Applicants lacking the following will be considered as not responsive. Nonresponsive applications will not be reviewed.

• New applications that are not submitted as part of the companion and required UM1 PAR-21-293 Clinical and Translational Science Award (UM1 Clinical Trial Optional).

• Resubmission of R25 Research Education applications that are not linked to a funded UM1.

 

Internal Deadline
External Deadline
01/12/2024

NIH PAR-21-336: 2023 Limited Competition: Mentored Research Career Development Program Award in Clinical and Translational Science Awards (CTSA) Program (K12 Clinical Trial Optional) - January Deadline

No applicants  // Limit: 1 // Tickets Available: 1 

 

The National Center for Advancing Translational Sciences (NCATS) will award Institutional Research Career Development (K12) programs through the Clinical and Translational Science Awards (CTSA). The purpose of this Funding Opportunity Announcement (FOA) is to encourage institutions to propose creative and innovative institutional research career development programs designed to prepare an outstanding heterogeneous pool of promising later stage postdoctoral fellows and junior faculty scholars in clinical and translational science who have made a commitment to independent research careers (i.e., tenure-track or equivalent faculty positions), and to facilitate their timely transition to more advanced support mechanisms, e.g., K08, K23, R01, R03, etc. Applicants must submit both a UM1 application to PAR-21-293: Clinical and Translational Science Award and a K12 application to this FOA.

This Funding Opportunity Announcement (FOA) allows appointment of Scholars (K12) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

 

With this solicitation for the K12 application, a separate, companion FOA solicits applications for a required UM1 (PAR-21-293). A UM1 hub application without the required companion K12 application will not be reviewed. The required K12 application will only be awarded if the UM1 application is awarded. Initial and resubmission of K12 will be accepted concurrently or if the UM1 application is awarded.

The application must provide a specific plan describing the partnership between the UM1, the required K12 and any optional components. The applicant institution must be the UM1 applicant. The UM1 institution must have a strong and high-quality research program in the area(s) proposed under this K12 FOA and must have the requisite faculty, staff, potential scholars and facilities on site to conduct the proposed institutional program. In many cases, it is anticipated that the proposed program will complement other ongoing career development programs occurring at the applicant institution and that a substantial number of program faculty will have active research projects in which participating scholars may gain relevant experiences consistent with their research interests and goal.

The sponsoring institution must assure support for the proposed program. Appropriate institutional commitment to the program includes the provision of adequate staff, facilities, and educational resources that can contribute to the planned program.

The PD/PI should be an established investigator in the scientific area in which the application is targeted and capable of providing both administrative and scientific leadership to the development and implementation of the proposed program. The PD/PI will be responsible for the selection and appointment of trainees to the approved research training program, and for the overall direction, management, administration, and evaluation of the program. The PD/PI will be expected to monitor and assess the program and submit all documents and reports as required. The PD/PI has responsibility for the day to day administration of the program and is responsible for appointing members of the Advisory Committee (when applicable), using their recommendations to determine the appropriate allotment of funds.

Only one K12 application will be awarded if the UM1 application is awarded. If the UM1 is awarded and the initial K12 is not, the K12 application may be resubmitted. If the UM1 (A0) application is not awarded, then the K12 (A0) will not be awarded.

NCATS solicits the submission of one set of companion applications. With this FOA for the K12 application, a separate, companion FOA seeks applications for a required UM1 (PAR-21-293: Clinical and Translational Science Award). The UM1 and initial K12 applications must be submitted concurrently; a K12 application without the required companion UM1 application will not be reviewed. The required K12 application will only be awarded if the UM1 application is awarded. 

Funding Type
Internal Deadline
External Deadline
01/29/2024

NISG RFA-DK-25-003: 2024 Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional)

No Applicants // Limit: 1 // Tickets Available: 1 

 

This Notice of Funding Opportunity (NOFO) invites applications for Silvio O. Conte Digestive Diseases Research Core Centers (DDRCCs). The DDRCCs are part of an integrated program of digestive and liver diseases research support provided by the NIDDK.  The purpose of this Centers program is to bring together basic and clinical investigators as a means to enhance communication, collaboration, and effectiveness of ongoing research related to digestive and/or liver diseases within the NIDDK's mission.  DDRCCs are based on the core concept, whereby shared resources aimed at fostering productivity, synergy, and new research ideas among the funded investigators are supported in a cost-effective manner.  Each proposed DDRCC must be organized around a central theme that reflects the focus of the digestive or liver diseases research of the Center members. The central theme must be within the primary mission of the NIDDK, and not thematic areas for which other NIH Institutes or Centers are considered the primary source of NIH funding. 

This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Funding Type
Internal Deadline
External Deadline
02/22/2024

NIH PAR-23-286: 2024 NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)

 Limit: 4 // Tickets Available: 3 // S. Yeo (Postdoctoral UACC)

 

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.

This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFOs (PAR-23-287 or PAR-23-288).

Each eligible institution (defined as having a unique UEI number or NIH IPF number) may submit up to a combined total of four applications (one in Cancer Data Science, one in Cancer Control Science, one in Molecular/Precision Cancer Prevention, and one in Other Cancer Research) to any companion NOFO or any combination of companion NOFOs (PAR-23-286PAR-23-287, and/or PAR-23-288).

Funding Type
Internal Deadline
External Deadline
02/14/2024

NIH PAR-23-287: 2024 NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)

No Applicants // Limit: 4 // Tickets Available: 4

 

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.

This notice of funding opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286).

Each eligible institution (defined as having a unique UEI number or NIH IPF number) may submit up to a combined total of four applications (one in Cancer Data Science, one in Cancer Control Science, one in Molecular/Precision Cancer Prevention, and one in Other Cancer Research) to any companion NOFO or any combination of companion NOFOs (PAR-23-286PAR-23-287, and/or PAR-23-288).

 

Funding Type
Internal Deadline
External Deadline
02/14/2024

NIH PAR-23-288: 2024 NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)

No Applicants // Limit: 4 // Tickets Available: 4

 

The purpose of the NCI Pathway to Independence Award for Early-Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions. The program will provide independent NCI research support during this transition to help awardees launch competitive, independent research careers. Researchers in the scientific areas of cancer control, cancer prevention and cancer data sciences are especially encouraged to work with their institutions to apply.

This Notice of Funding Opportunity (NOFO) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Those not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (PAR-23-286).

This Notice of Funding Opportunity is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this NOFO include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion NOFO.

The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

Each eligible institution (defined as having a unique UEI number or NIH IPF number) may submit up to a combined total of four applications (one in Cancer Data Science, one in Cancer Control Science, one in Molecular/Precision Cancer Prevention, and one in Other Cancer Research) to any companion NOFO or any combination of companion NOFOs (PAR-23-286PAR-23-287, and/or PAR-23-288).

Funding Type
Internal Deadline
External Deadline
02/14/2024

NIH RFA-NS-24-014: 2023 Blueprint and BRAIN Initiative Program for Enhancing Neuroscience Diversity through Undergraduate Research Education Experiences (BP BRAIN-ENDURE) (R25 Clinical Trial Not Allowed)

No Applicants // Limit: 1 // Tickets Available: 1 

 

The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.

The fully integrated educational activities should prepare undergraduate students from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences, to enter Ph.D. degree programs in the neurosciences. To accomplish this goal, this initiative will provide institutional awards to develop neuroscience research education programs comprised of collaborative partnerships integrated across different educational institution types.

Funding Type
Internal Deadline
External Deadline
02/15/2024

NIH 2024 S10 Instrumentation Programs: Shared Instrumentation Grant Program (SIG) & High-End Instrumentation Grant Program (HEI)

Institutionally coordinated

 

ORIP's S10 Instrumentation Grant Programs support purchases of state-of-the-art commercially available instruments to enhance research of NIH-funded investigators. Instruments that are awarded are typically too expensive to be obtained by an individual investigator with a research project grant. Every instrument awarded by an S10 grant is to be used on a shared basis, which makes the programs cost-efficient and beneficial to thousands of investigators in hundreds of institutions nationwide.

To be eligible for an S10 award, an institution must identify three or more principal investigators with active NIH research awards who demonstrate a substantial need for the requested instrument. Matching funds are not required. Types of instruments supported by S10 funding include, but are not limited to, X-ray diffraction systems, nuclear magnetic resonance (NMR) and mass spectrometers, DNA and protein sequencers, biosensors, electron and confocal microscopes, cell-analyzers, and biomedical imagers.

Active RFPs are: 

There is no restriction on the number of applications an institution can submit to the SIG and/or High-End HEI Grant Programs. However, institutional internal coordination is required for concurrent SIG or HEI applications to verify each proposal is requesting different types of equipment.

Solicitation 

Internal Deadline
External Deadline
06/03/2024

NIH PAR-23-306: 2024 Biomedical Research Facilities (C06 Clinical Trial Not Allowed)

Institutionally Coordinated // Limit: 1 // M. Dake ( University of Arizona Health Sciences)

 

Moreover, institutions with C06 awards funded under the Biomedical Research Facility Program (NOFOs PAR-21-139PAR-22-088 or PAR-23-045) are not eligible to apply to this NOFO, provided the awards are active on the receipt date for this NOFO. Thus, only one C06 Biomedical Research Facility active award per institution would be allowed at any given time.

This Notice of Funding Opportunity (NOFO) invites applications from eligible academic and research institutions to apply for funding to modernize existing or construct new biomedical research facilities. Applications will be accepted from public and private nonprofit institutions of higher education as well as from non-profit research organizations. Applications from both research-intensive institutions and Institutions of Emerging Excellence (IEE) in biomedical research, both highly resourced and low-resourced institutions, from all geographic regions in the nation are strongly encouraged.

NIH recognizes the importance of all institutions of higher learning in contributing to the nation’s research capacity. The goal of this NOFO is to modernize biomedical research infrastructure to strengthen biomedical research programs. Each project is expected to provide long-term improvements to the institutional research infrastructure. Intended projects are the construction or modernization of core facilities and the development of other shared research infrastructure serving an institution-wide research community with broad impact on biomedical research.

Internal Deadline
External Deadline
01/25/2024

NIDCD Early Career Research (ECR) Award

The NIDCD Early Career Research (ECR) Award (R21) is intended to support both basic and clinical research from scientists who are beginning to establish an independent research career. It cannot be used for thesis or dissertation research. The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NIDCD ECR Award R21 grant mechanism supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. Irrespective of the type of project, the intent of the NIDCD ECR Award R21 is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.

Only one NIDCD ECR Award (R21) application may be submitted by a PD/PI per due date. PD/PIs who successfully obtained an NIDCD Small Grant award are ineligible for an NIDCD ECR Award (R21).

Applicants may not submit an NIDCD R01, R15 or R21 application for the same review cycle that the NIDCD ECR Award application is submitted. In such cases, the NIDCD ECR Award R21 application will be withdrawn.

External Deadline
02/27/2025(Anticipated)